From the archive1 min read
Hydroxyurea to Lower Transcranial Doppler Velocities and Prevent Primary Stroke: The Uganda NOHARM Sickle Cell Anemia Cohort
In sub-Saharan Africa, sickle cell anemia (SCA) remains a significant public health problem with high mortality: an estimated 50-90% of affected children die before 5 years of…
Scientific Articles · Hydroxyurea/Hydria/Droxia · Transcranial Doppler Ultrasonography
About this article
- Source:
- oneSCDvoice(opens in a new tab)
- Published
- Last updated
oneSCDvoice
In sub-Saharan Africa, sickle cell anemia (SCA) remains a significant public health problem with high mortality: an estimated 50-90% of affected children die before 5 years of age. A high prevalence of stroke is particularly devastating for children and has substantial morbidity. Hydroxyurea is now recommended across the lifespan as a safe and effective disease-modifying therapy for SCA, but is not routinely available in sub-Saharan Africa.
NOHARM (NCT01976416), a randomized double-blinded, placebo-controlled trial, was among the first prospective studies to investigate hydroxyurea treatment for children with SCA living in a malaria endemic region within Africa. The NOHARM trial consisted of a blinded phase (Year 1) and an open-label phase (Year 2). Initially children 1.00-4.99 years of age were randomized either to placebo or fixed-dose hydroxyurea (20 mg/kg/day). The Year 1 results demonstrated that short-term hydroxyurea treatment was both safe and efficacious in this young patient population living in a malarial endemic region. We now analyze Year 2 data from the open-label phase, in which all NOHARM participants received hydroxyurea at 20 mg/kg/day, to compare the effects of hydroxyurea on SCA-related morbidity and also to provide serial transcranial Doppler (TCD) data, which were not included in the original randomized report.
Abstract source